International St. Mary’s Hospital and Miracell Sign Joint Stem Cell Research Agreement
International St. Mary’s Hospital and Miracell Sign Joint Stem Cell Research AgreementCooperation to Expand Clinical and Stem Cell Research and Development, and Invigorate the Medical and Biohealth Sectors Catholic Kwandong University International St. Mary’s Hospital (President Kim Hyun-soo) announced on the 27th that it had signed a business agreement with Miracell (CEO Shin Hyun-soon) for joint stem cell clinical research. The signing ceremony was attended by Father Kim Hyun-soo, President of International St. Mary’s Hospital; Professor Chae Dong-sik (Orthopedic Surgery), Director of the Cell Therapy Center; Miracell CEO Shin Hyun-soon, and representatives from both institutions. Under this agreement, International St. Mary’s Hospital will establish a cooperative relationship with Miracell to promote research and development to improve national health and advance future medical technologies. To this end, the two organizations agreed to closely collaborate on: ▲ joint clinical and stem cell research and development; ▲ research and development in future medical fields; and ▲ the revitalization of the medical and biohealth sectors. Father Kim Hyun-soo, Director of International St. Mary’s Hospital, said, “Contributing to the improvement of national health and welfare through cutting-edge medical care is a truly valuable endeavor.” “I hope this collaboration will provide an opportunity to provide more effective treatment to patients.” Meanwhile, Miracell is a stem cell company that conducts joint research and development with domestic and international medical institutions to specialize in safe stem cell treatments.
Miracell Presents Stem Cell Treatment Results for Intractable Skin Diseases at the World Congress of Aesthetic Plastic Surgery in Bangkok
Miracell presented its stem cell treatment for refractory skin conditions at the World Congress of Aesthetic Plastic Surgery in Bangkok. [Edaily Reporter Lee Soon-yong] Stem cell specialist Miracell (CEO Shin Hyun-soon) announced on the 5th that it presented the results of its “stem cell treatment for refractory skin” in collaboration with plastic surgeon Professor Park Eun-soo (Soonchunhyang University Bucheon Hospital) at the International Congress of Aesthetic Plastic Surgery (MCAS ASIA 2022), held in Bangkok, Thailand from September 29 to October 1. IMCAS ASIA is the Asian regional conference of IMCAS, one of the world’s top three aesthetic plastic surgery societies. It brings together plastic surgeons, dermatologists, and industry leaders from Asia and around the world to present and share the latest technologies and research in the field of medical aesthetics. Professor Eunsoo Park, who has conducted national projects on chronic wounds (such as diabetic foot and ischemic ulcers) and has conducted extensive research on regenerative treatments,attended this conference as a panelist and drew the attention of physicians worldwide with a presentation on “Cell Therapy and Regenerative Medicine, Advanced Cell and Tissue Therapy for Skin Aging and Lesions.” For the treatment of psoriasis, a refractory skin disease, stem cells selectively collected using the “Smart Mcell 2,” a cutting-edge stem cell extraction system developed by Miracell. This system regenerates damaged tissue by injecting total cells, including stem cells with a cell survival rate of up to 99%, growth factors, white blood cells, and platelets, into the wound. “Smart Mcell 2” is a cutting-edge biodevice that has received New Medical Technology Certification from the Ministry of Health and Welfare, been selected as a Public Innovation Product by the Public Procurement Service, and has been registered with the US FDA. It is recognized as an essential system in regenerative medicine. CEO Shin Hyun-soon stated, “There have been many cases of actual results from stem cell therapy for psoriasis, a rare and intractable immune disease with low treatment efficacy. At this international conference, I was able to present on the connection between immune diseases and the skin, and the results of cell therapy.” He continued, “Doctors from around the world have been asking questions about the specific stem cell treatments we used, including IV injections and topical skin treatments, and have raved about the excellent treatment results.” CEO Shin continued, “I am proud that this presentation has elevated Korea’s status in the advanced regenerative medicine bio market. We will continue to conduct clinical trials using our stem cell extraction system to treat more patients and achieve better outcomes.” Meanwhile, Miracell plans to attend “Medica 2022 in Germany,” a global medical industry gathering, on November 14th.